These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. Waxman AB; Zamanian RT Am J Cardiol; 2013 Mar; 111(5 Suppl):1A-16A; quiz 17A-19A. PubMed ID: 23414683 [TBL] [Abstract][Full Text] [Related]
30. YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice. Huh JW; Kim SY; Lee JH; Lee YS Pulm Pharmacol Ther; 2011 Dec; 24(6):638-46. PubMed ID: 21963997 [TBL] [Abstract][Full Text] [Related]
31. A descriptive evaluation of warfarin use in patients with pulmonary arterial hypertension. Irwin AN; Johnson SG; Joline BR; Delate T; Witt DM Thromb Res; 2014 May; 133(5):790-4. PubMed ID: 24642007 [TBL] [Abstract][Full Text] [Related]
32. [Coagulation and fibrinolytic abnormality related to endothelial injury in pulmonary arterial hypertension]. Sakamaki F Nihon Rinsho; 2001 Jun; 59(6):1053-8. PubMed ID: 11411112 [TBL] [Abstract][Full Text] [Related]
33. Neurohormonal activation and pharmacological inhibition in pulmonary arterial hypertension and related right ventricular failure. Ameri P; Bertero E; Meliota G; Cheli M; Canepa M; Brunelli C; Balbi M Heart Fail Rev; 2016 Sep; 21(5):539-47. PubMed ID: 27206576 [TBL] [Abstract][Full Text] [Related]
34. Effect of warfarin on survival in patients with concomitant left ventricular systolic dysfunction and pulmonary hypertension: a population cohort study. Goudie A; Elder D; Deshmukh H; Szwejkowski BR; Lang CC; George J Eur J Heart Fail; 2015 Jan; 17(1):90-7. PubMed ID: 25427720 [TBL] [Abstract][Full Text] [Related]
35. Pulmonary arterial hypertension and women. De Marco T Cardiol Rev; 2006; 14(6):312-8. PubMed ID: 17053380 [TBL] [Abstract][Full Text] [Related]
36. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. Johnson SR; Granton JT; Tomlinson GA; Grosbein HA; Le T; Lee P; Seary ME; Hawker GA; Feldman BM J Rheumatol; 2012 Feb; 39(2):276-85. PubMed ID: 22247353 [TBL] [Abstract][Full Text] [Related]
37. Pulmonary arterial hypertension: from pathophysiology to management. Hernández-Rivera H; Martínez-González H; Casal J; Rodríguez-Ospina L Bol Asoc Med P R; 2011; 103(1):34-40. PubMed ID: 21696100 [TBL] [Abstract][Full Text] [Related]
38. Pulmonary hypertension in connective tissue diseases: an update. Aithala R; Alex AG; Danda D Int J Rheum Dis; 2017 Jan; 20(1):5-24. PubMed ID: 28205373 [TBL] [Abstract][Full Text] [Related]
39. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639 [TBL] [Abstract][Full Text] [Related]
40. Pulmonary arterial hypertension: a current review of pharmacological management. Sahni S; Ojrzanowski M; Majewski S; Talwar A Pneumonol Alergol Pol; 2016; 84(1):47-61. PubMed ID: 26693827 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]